Vanda Pharmaceuticals Inc.
Financials
Valuation Metrics
Vanda Pharmaceuticals Inc.'s Market Cap is $308M. At end of 2025 it was $521M. Ranked #2941 of 3,121 in US market (top 94%), #1325 of 1,463 on NASDAQ (top 91%), #242 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $308M | US#2,941/3,121 Sec#242/266 |
| Revenue | $216M | US#2,561/3,121 Sec#108/266 |
| Net Income | $-275M | US—/3,121 Sec—/266 |
| Total Assets | $412M | US#2,836/3,121 Sec#183/266 |
| Net Assets | $220M | US#2,654/3,121 Sec#182/266 |
| Employees | 533 | US#2,256/3,121 Sec#80/266 |
| Value | ||
| P/B | 1.40x | US#780/3,121 Sec#30/266 |
| P/S | 1.43x | US#991/3,121 Sec#17/266 |
| FCF Yield | -46.45% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -124.83% | US#2,813/3,121 Sec#208/266 |
| ROA | -66.64% | US#3,028/3,121 Sec#236/266 |
| Op. Margin | -86.07% | US#2,722/3,121 Sec#119/266 |
| Revenue Growth | 6.02% | US#1,701/3,121 Sec#111/266 |
| Financial Health | ||
| Debt Ratio | 87.33% | US#968/3,121 Sec#162/266 |
| Total Debt | $23M | US#2,736/3,121 Sec#185/266 |
| FCF | $-143M | US#2,708/3,121 Sec#173/266 |
| Cash | $56M | US#2,543/3,121 Sec#220/266 |
| Current Ratio | 1.61x | US#1,550/3,121 Sec#236/266 |
| Performance | ||
| 1Y Return | 13.27% | US#1,283/3,121 Sec#161/266 |
| 1M Return | -8.08% | US#1,905/3,121 Sec#150/266 |
| From 52W High | -48.49% | US#2,685/3,121 Sec#210/266 |
| 1Y MDD | -48.43% | US#2,390/3,121 Sec#174/266 |
| Trading | ||
| Volume | 1,532,397 shares | US#1,779/3,121 Sec#187/266 |
| Trading Value | $8M | US#2,791/3,121 Sec#238/266 |
| Per Share | ||
| EPS | $-4.57 | US—/3,121 Sec—/266 |
| BPS | $3.66 | US#2,407/3,121 Sec#150/266 |
Company Info
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.